Columbus, OH – On Tuesday, The Buckeye Institute submitted written testimony (see full text below or download a PDF) to the Ohio House Insurance Committee on the policies in Ohio House Bill 192, urging lawmakers to adopt “sound, market-based reforms that will lower regulatory barriers to healthcare, encourage drug innovation, help maintain drug affordability, and improve patient health.”

In his testimony, Rea S. Hederman Jr., vice president of policy at The Buckeye Institute, noted that some policies in House Bill 192, which imposes a minimum government-mandated dispensing fee on Ohio pharmacies, will “likely raise consumer prices at the pharmacy rather than lower them.” Hederman pointed out that such policies at the federal level have “already raised dispensing fees under Medicaid” and that the new rule “will use government influence to benefit large chain pharmacies…and it will harm retail consumers by reducing price competition and making the trip to the pharmacy more expensive.”

To bring down healthcare costs and increase accessibility, Hederman encouraged lawmakers to adopt policies that:

• Reduce regulatory barriers; 
• Encourage market growth, innovation, and competition; and 
• Prevent undue government influences that restrict supply and raise consumer prices.

# # #

Market-Based Reforms Needed to Address Drug Affordability

Interested Party Testimony
Ohio House Insurance Committee
Ohio House Bill 192

Rea S. Hederman Jr.
Vice President of Policy
The Buckeye Institute
November 18, 2025

As Submitted

Chair Lampton, Vice Chair Craig, Ranking Member Hall, and members of the Ohio House Insurance Committee, thank you for the opportunity to submit written testimony regarding Ohio House Bill 192.

My name is Rea S. Hederman Jr. I am the vice president of policy at The Buckeye Institute, an independent research and educational institution—a think tank—whose mission is to advance free-market public policy in the states.

Retail drugs account for roughly 10 percent of all healthcare costs in Ohio, a significant sum that stokes patients’ understandable concern about pharmaceutical prices. Ohio needs sound, market-based reforms that will lower regulatory barriers to healthcare, encourage drug innovation, help maintain drug affordability, and improve patient health. House Bill 192 does and does not do that.

Instead of streamlining government rules or making healthcare and drug markets more competitive, House Bill 192 issues another government mandate that will likely raise consumer prices at the pharmacy rather than lower them. Currently, pharmacists charge dispensing fees to cover their service of filling prescriptions. Such fees are charged in addition to the price of the prescription drugs themselves. House Bill 192 sets an artificial minimum fee that pharmacists may charge for filling prescriptions. The bill ties the new minimum fee to the average dispensing fee across the state, which means that the higher the average, the higher the minimum fee will be—and that creates an incentive to raise the average in order to raise the minimum. Not surprisingly then, such a mandate has already raised dispensing fees under Medicaid, and House Bill 192 will yield similar results in the private sector. The new rule will use government influence to benefit large chain pharmacies that tend to have lower dispensing fees than smaller pharmacies, and it will harm retail consumers by reducing price competition and making the trip to the pharmacy more expensive.  

The General Assembly should continue focusing on reducing regulatory barriers; encouraging market growth, innovation, and competition; and preventing undue government influences that restrict supply and raise consumer prices. House Bill 192’s credentialing provisions do that, but the bill’s mandatory minimum pharmacy dispensing fees do not. 

Thank you for your time and attention to this issue. 

# # #